Abingdon, United Kingdom

Immunocore Limited


USPTO Granted Patents = 48

% Expired Patents = 10.4



Trademarks = 15

Forward Citations = 408

Loading Chart...
Loading Chart...

78 inventors (with patents filed for the assignee):

goldMedal Bent Karsten Jakobsen (26 out of 32 patents)

silverMedal Yi Li (14 out of 24 patents)

bronzeMedal Peter Eamon Molloy (12 out of 17 patents)

4.  Nathaniel Ross Liddy (11 out of 11 patents)

5.  Annelise Brigitte Vuidepot (8 out of 8 patents)

6.  Jonathan Michael Boulter (6 out of 9 patents)

7.  Steven Mark Dunn (6 out of 9 patents)

8.  Chandramouli Reddy Chillakuri (5 out of 5 patents)

9.  Stephen Harper (5 out of 5 patents)

10.  Tara Mahon (5 out of 6 patents)

11.  Alex Powlesland (4 out of 4 patents)

12.  Philip William Addis (4 out of 4 patents)

13.  Dhaval Jaykant Sangani (3 out of 3 patents)

14.  Graham Anthony Hood (3 out of 3 patents)

15.  Lucy Boulter, Legal Representative (3 out of 3 patents)


Core Competencies:
CD1a Antagonist
PD-1 Agonist
HBV Envelope Protein
HIV Binding Molecules
TCR Libraries
Bifunctional Polypeptides
Modified T Cell Receptors
High Affinity TCRs
MHC Complexes
Peptide Binding
T Cell Receptor Display
TCR Mutants

48 patents:

Immunocore Limited, headquartered in Abingdon, UK, specializes in the development of innovative therapies leveraging T cell receptor technology. The company focuses on creating binding molecules and high-affinity T cell receptors that target specific antigens, including those associated with HIV. Its research encompasses TCR libraries and bifunctional polypeptides, aiming to enhance immune responses against various diseases. Immunocore's advancements in modified T cell receptors position it at the forefront of immunotherapy and precision medicine.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Immunocore Limited
48 Patents

#5 in Abingdon

#371 in United Kingdom

#14,527 in the World

Abingdon, GB
Abingdon, United Kingdom
Forward Citations = 408

78 inventors:

Please report any incorrect information to [email protected]
Loading…